Clinical Trial Update: Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia [Phase 2]

View source ↗

Summary

A Phase 2 study assessing fixed dosing of AMG 223 in adults with chronic kidney disease on hemodialysis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• AMG 223

Snippet

Sponsor: Amgen | Conditions: End Stage Renal Disease, Chronic Kidney Disease | Phase 2 | Status: COMPLETED